PMV Pharmaceuticals develops oral small molecule cancer drugs that target mutations in the p53 protein. It last closed at $1.22 on Nov 17, up 2.52% on the day.
Only 1 firm rated PMVP in the past 90 days, not enough for a consensus
Average 12-month target
$5.00
▲ 309.8% upside
Based on 1 analyst who set a price target on PMVP in the past 90 days. The average target is $5.00, with a high of $5.00 and a low of $5.00, compared with the last close of $1.22.
Low $5.00Avg $5.00High $5.00
Blue marker: last close $1.22
Highest target$5.00
Average target$5.00
Lowest target$5.00
Latest rating changes
HC Wainwright & Co.Reiterated
Sep 4Buy$5
Ladenburg ThalmannAssumed coverage
Jul 8Buy$3
Date
Firm
Action
Rating
Price target
Sep 4
HC Wainwright & Co.
Reiterated
Buy
$5
Jul 8
Ladenburg Thalmann
Assumed coverage
Buy
$3
Loading…
Technical Analysis
PMVP · as of the Nov 17 close · updated after every close
Turning down
The stock is 5% below its 20 day and 13% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 44). The nearest support is the swing low (Jul 6) at $1.20, and the nearest resistance the Pivot R1 at $1.28.
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 8.6%/day
Key levels
$1.9152 week high+56.6%
$1.3850 day average+13.1%
$1.32100 day average+8.2%
$1.31200 day average+7.4%
$1.29Swing high (Jun 2)+5.7%
$1.2820 day average+4.9%
$1.28Pivot R1+4.9%
$1.22Last close
$1.20Swing low (Jul 6)−1.6%
$1.17Pivot−4.1%
$1.12Pivot S1−8.2%
$1.0252 week low−16.4%
Indicators
RSI (14)
44.43
Middle of its range
Neutral
MACD
-0.04
Below its signal line
Bearish
Stochastic
28.5
Middle of its range
Neutral
ADX (14)
21.2
Weak trend
Williams %R
-59.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-128.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.6%
Change over 10 sessions
Bearish
ATR (14)
$0.11
Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 18.5%/day
Key levels
$1.9152 week high+56.6%
$1.3850 day average+13.1%
$1.32100 day average+8.2%
$1.31200 day average+7.4%
$1.29Swing high (Jun 2)+5.7%
$1.2820 day average+4.9%
$1.28Pivot R1+4.9%
$1.22Last close
$1.20Swing low (Jul 6)−1.6%
$1.17Pivot−4.1%
$1.12Pivot S1−8.2%
$1.0252 week low−16.4%
Indicators
RSI (14)
46.79
Middle of its range
Neutral
MACD
0.00
Below its signal line
Bearish
Stochastic
21.4
Middle of its range
Neutral
ADX (14)
13.8
No clear trend
Williams %R
-82.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-86.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−12.9%
Change over 10 sessions
Bearish
ATR (14)
$0.23
Typical daily range, 18.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PMVP
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PMVP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PMVP usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PMVP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMVP is in one of them and how their past PMVP trades turned out.
PMV Pharmaceuticals is a cancer drug developer based in Princeton, New Jersey. It develops oral small molecule medicines that aim to restore normal function to mutant p53, a protein that helps stop cancer growth when it works properly. Its lead product candidate, rezatapopt, targets a specific p53 mutation found in several solid tumors, including some ovarian, lung and colorectal cancers. The company's therapies are intended for cancer patients whose tumors carry these mutations.